

PROGRAM



Bio-Neuroscience

Amsterdam, 24th-26th February, 2026

THE GLOBAL SUMMIT FOR LEADERS
AND DECISION-MAKERS IN
NEUROSCIENCES DRUG
DEVELOPMENT

Key Opinion Leaders
Industry Executives
Startups Founders
C-level Executives
Investors



INSIGHT - ACCESS - ENGAGEMENT - IMPACT

AN INITIATIVE OF



CO-ORGANIZED WITH





14:00

COFFEE & REGISTRATION

15:00

Roundtable Networking - Coffee and a Series of Networking Tables

Participant networking at a series of pre-scheduled roundtables for accelerated introductory networking.

15:00

Pre-Summit Roundtable Discussion - Innovation in BoNT Based Therapies for Neurological and Psychiatric Disorders

Moderator: Christian J Suojanen, CEO - Broadreach Global

Stefan König	CEO - Merz Therapeutics
Eric Finzi	Co-Founder - Healis Therapeutics
Marc Axel Wollmer	Head of department, Department of Old Age Psychiatry - Asklepios Clinic North - Ochsenzoll
Tillmann Krüger	Associate Professor, Deputy Head of Department - Psychiatry, Social Psychiatry and Psychotherapy, Head of Section of Clinical Psychology & Sexual Medicine - Hannover Medical School

15:45

COFFEE BREAK

16:00

Welcome to Bio-Neuroscience: Official Inauguration

Christian J Suojanen	CEO - Broadreach Global
Prisca Leferink	Business Development - Amsterdam Neuroscience, Amsterdam UMC

16:30

The need for Innovation in Pre-Clinical and Para-Clinical Models

Moderator: Christian J Suojanen, CEO - Broadreach Global

José Luís Lanciego	Laboratory of Gene Therapy for Parkinson's Disease - CIMA, University of Navarra, & President - European Brain Foundation
Claudia Persoon	Head - Neurospecter
Joshua Bagely	Chief Scientific Officer - ahead bio AG



DAY I

TUESDAY 24 FEB. 2026



Bio-Neuroscience

17:15

Innovation in Biomarkers to accelerate clinical research and improve clinical care

Joachim Reischl

VP & Franchise Head, Neurodegenerative Disease, Center of Innovation - Danaher Diagnostics

Charlotte Teunissen

Professor in Neurochemistry - Amsterdam UMC

18:00

Welcome Reception Remarks

18:05

WELCOME RECEPTION & NETWORKING



Bio-Neuroscience



Bio-Neuroscience



08:15

REGISTRATION OPENS, COFFEE & NETWORKING

09:00

Opening Remarks

Christian J Suojanen

CEO – Broadreach Global

Pieter van Bokhoven

Chief Scientific Officer - IXA Amsterdam
Neuroscience UMC

09:15

The Regulatory Perspective in Neuroscience Drug Development

Moderator: Arno de Wilde, Managing Director – EQT Life Sciences

Violeta Stoyanova-Beninska

Senior Scientific Specialist, Office of Therapies for neurological and psychiatric disorders
Former Chair of Committee for Orphan Medicinal Products - European Medicines Agency
Chair of Regulatory Science Committee - International Rare Disease Research Consortium

10:00

Therapeutics Development for Rare Neurological Diseases; Financing, Clinical and Regulatory Challenges and the Patient and Startup Perspective

Discussion Panel

Moderator: Yael Weiss, CEO - Mahzi Therapeutics

A discussion with stakeholders in rare pediatric neurological disease innovation; from rare families developing therapies, to KOL collaborators and specialized industry partners.

Stuart Cobb

Chief Scientific Officer- Neurogene Inc,
Professor of Translational Neuroscience - The University of Edinburgh

Andy Stevenson

Head of Fundraising - Reverse Rett

10:45

NETWORKING COFFEE BREAK



11:15

The Investment Bank Perspective: Navigating the State of Capital Markets and M&A as it impacts Neuroscience Drug Development

Moderator: Bruce Leuchter, President & CEO - Neurvati Neurosciences

Kevin Sheridan	Joint Global Head of Healthcare Investment Banking - Jefferies LLC
Eric Stewart	Senior Managing Director, Healthcare Mergers & Acquisitions - Leerink Partners
Sven Pfeiffer	Partner, Strategic Advisory Group - PJT Partners

12:00

Investor Session - The current Investment Landscape for CNS Neuroscience Drug Development

In light of evolving geopolitical, market, and regulatory conditions - what does it mean for private biotech?

Moderator: Hakan Goker, Managing Director & Head of Life Sciences - M Ventures

Thomas Michael Thestrup	Senior Principal - Angelini Ventures
Henrijette Richter	Managing Partner - Sofinnova Partners
Joao Barbosa da Silva	Investor - re.Mind Capital
Keno Gutierrez	General Partner - BioGeneration Ventures (BGV)

12:45

LUNCH & NETWORKING BREAK - HOSTED BY MERZ THERAPEUTICS



THERAPEUTICS

Better outcomes for more patients.

14:00

Fireside Chat - A Strategic Venture to develop a Disease Modifying Therapy for GBA Parkinson's Disease

Moderator: Kees Been, CEO, Kynexis Therapeutics

António Portela	CEO - BIAL
-----------------	------------



14:45

Neuroinflammation; tackling indications from MS to PD and AD
Key advances, core challenges, and strategies going forward in current market conditions.

Moderator: Marco Giorgetti, Global Head Alliance Management, Danaher

Jing Wang

Co-Founder & Chief Executive Officer -
Myrobalan Therapeutics

Niels Plath

Chief Scientific Officer - Muna Therapeutics

15:30

NETWORKING COFFEE BREAK

16:00

Venture Philanthropy, Charity and Foundation Financed Neuroscience Drug Development

Moderator: Andrea Soto Padilla, Business Development - Amsterdam Neuroscience, Amsterdam UMC

Giovanna Lalli

Director of Strategy & Operations - LifeArc

Opher Kornfeld

Director, Translational Research and Development
- SPARK NS

Lynsey Bilisland

Managing Director of Parkinson's Virtual
Biotech - Parkinson's UK

16:45

COMPANY PRESENTATION SESSION

Selected companies present to an industry & investor panel

AlzeCure Pharma - Martin Jönsson - CEO

London Research & Pharmaceuticals Corporation - Abdelrahman Lawendy - CEO

discoveric bio alpha - Oliver Eckelmann - CEO

FundaMental Pharma GmbH - Dirk Beher - CEO

Mair Therapeutics - Vasily Kazey - CEO

TRIMTECH Therapeutics - Nicki Thompson - CEO

17:45

END OF DAY II & NETWORKING RECEPTION - HOSTED BY DANAHER





08:15

REGISTRATION OPENS, COFFEE & NETWORKING

09:00

Keynote - Engineering AAVs for human CNS Gene Therapy

Ben Deverman

Director, Vector Engineering at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard

10:00

Gene therapy 2.0 in Neuroscience

The evolution of gene therapies, current approaches, opportunities and challenges from the scientific, clinical, regulatory and market perspectives.

Moderator: Robert Thorne, Denali Fellow – Denali Therapeutics, Past President - International Brain Barriers Society (IBBS)

Alex Bloom

CTO - AviadoBio

Andrew Steinsapir

Acting CTO - Apertura Gene Therapy, & Director, Gene Therapy Program Lead - Deerfield Management

Marco Weinberg

Senior Vice President, Head of Research, uniQure

Sander van Deventer

President R&D, VectorY Therapeutics

10:45

NETWORKING COFFEE BREAK

11:15

Fireside Chat - Anatomy of a deal; Discussing the Angelini Pharma and GRIN Therapeutics deal, one year in

Moderator: Christian J. Suojanen, CEO – Broadreach Global

Jacopo Andreose

Board Member - Angelini Industries and Grin Therapeutics

Bruce Leuchter

President & CEO - Nervati Neurosciences

12:00

Novel modalities, from Oligonucleotides to RNA Therapeutics in CNS Rare Diseases: Science, Approvals, Approaches and Deals.

Moderator: Pieter van Bokhoven, Chief Scientific Officer - IXA Amsterdam Neuroscience UMC

Maria Luisa Pineda

CEO & Co-Founder - Envisagenics

Tarek Samad

Senior Vice President & Global Head of Research - Lundbeck

Vikas Sharma

Chief Business Officer - QurAlis





12:45

LUNCH & NETWORKING BREAK

14:00

COMPANY COMPANY SESSION

Selected companies present to an industry & investor panel

Contineum Therapeutics - Daniel S. Lorrain - CSO
Priavoid GmbH - Antje Willuweit - Director, Preclinical Development
Tetraneuron - Ángel Lucio Pereira - CEO
Serenatis Bio - David Cavalla - Executive Chairman
Ultimate Medicine - Antal Szalay - CEO
Evox Therapeutics - Per Lundin - CEO & Co-Founder

14:45

Industry Panel - Partnering With Industry

Moderator: Christian J Suojanen, CEO - Broadreach Global

Jenny Laird	VP, Business Development Neuroscience - Eli Lilly Managing Director - Abbvie Ventures Director, Business Development & Licensing - MSD Global External CNS Research - Boehringer Ingelheim Global Head of Business Strategy & Portfolio Innovation - Merz Therapeutics
Claire Leurent	
Richard Reschen	
Christian Thomsen	
Karen LaRochelle	

15:45

Bio-Neuroscience Awards

Company Pitch Awards

16:00

Closing Remarks

16:15

END OF SUMMIT - NETWORKING RECEPTION





THANK YOU TO OUR SPONSORS

Gold Sponsors



THERAPEUTICS

Better outcomes for more patients.

Founding Sponsors



Bronze Sponsors



Partners



<p>An Initiative of:</p>	<p>Co-Organized with:</p>
	